Coherus Contact Information:
For Investors:
Head of Investor Relations
IR@coherus.com
![](https://ml.globenewswire.com/media/MTdjYTE0NDEtMWI5Yi00ODVjLWI1Y2YtZGMzMDNmZjkyZGUzLTEwMjI3MzE=/tiny/Coherus-BioSciences-Inc-.png)
2024 GlobeNewswire, Inc., source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 USD | -4.32% |
|
-23.12% | -60.06% |
Jul. 02 | Coherus BioSciences Grants Apotex License to Distribute Toripalimab in Canada | MT |
Jul. 01 | Baird Trims Price Target on Coherus BioSciences to $8 From $9, Maintains Outperform Rating | MT |
Coherus Contact Information:
For Investors:
Head of Investor Relations
IR@coherus.com
2024 GlobeNewswire, Inc., source
1st Jan change | Capi. | |
---|---|---|
-60.06% | 153M | |
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.56B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |